Using positron emission tomography and carbon 11-labeled pittsburgh compound B to image brain fibrillar β-amyloid in adults with down syndrome: Safety, acceptability, and feasibility

Archives of Neurology

Volumn 68, Issue 7, 2011, Pages 890-896

  Landt, Jennifer ^a   Carlos D'Abrera, J ^a   Holland, Anthony J ^a   Aigbirhio, Franklin I ^b   Canales, Roberto ^b   Hong, Young T ^b   Menon, David K ^a   Baron, Jean Claude ^b,d   Zaman, Shahid H ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ABSENCE OF SIDE EFFECTS; ADULT; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAFETY; UNITED KINGDOM;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID; BENZOTHIAZOLES; BRAIN; BRAIN MAPPING; DOWN SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; YOUNG ADULT;

EID: 79960193987     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.36     Document Type: Article

References (57)

1. Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. Eur J Public Health. 2007;17(2):221-225. (Pubitemid 46536733)
2. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17(3):278-282. (Pubitemid 15136603)
3. Mann DM. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev. 1988;43(2):99-136.
4. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol. 1989;46(8):849-853. (Pubitemid 19199367)
5. Hofman A, Rocca WA, Brayne C, et al; Eurodem Prevalence Research Group. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol. 1991;20(3):736-748.
6. Holland AJ, Hon J, Huppert FA, Stevens F. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J Intellect Disabil Res. 2000;44(pt 2):138-146. (Pubitemid 30386552)
7. Holland AJ, Hon J, Huppert FA, Stevens F, Watson P. Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br J Psychiatry. 1998;172:493-498. (Pubitemid 28247481)
8. Holland AJ, Oliver C. Down's syndrome and the links with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1995;59(2):111-114.
9. Coppus A, Evenhuis H, Verberne GJ, et al. Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res. 2006;50(pt 10):768-777. (Pubitemid 44336413)
10. Burger PC, Vogel FS. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am J Pathol. 1973;73(2):457-476.
11. Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984;10(3):185-207. (Pubitemid 14121330)
12. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology. 1985;35(7):957-961. (Pubitemid 15026265)
13. Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci. 1989;89(2-3):169-179. (Pubitemid 19052948)
14. Ikeda S, Yanagisawa N, Allsop D, Glenner GG. Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains. Lab Invest. 1989;61(1):133-137. (Pubitemid 19203861)
15. Rumble B, Retallack R, Hilbich C, et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med. 1989;320(22):1446-1452. (Pubitemid 19143709)
16. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome: quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol. 1995;52(4):379-391.
17. Sadowski M, Wisniewski HM, Tarnawski M, Kozlowski PB, Lach B, Wegiel J. Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology. Acta Neuropathol. 1999;97(2):156-164. (Pubitemid 29134544)
18. Goldgaber D, Lerman MI, McBride WO, Saffiotti U, Gajdusek DC. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease, Down's syndrome and aging. J Neural Transm Suppl. 1987;24:23-28.
19. St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science. 1987;235(4791):885-890. (Pubitemid 17019126)
20. Hardy JA, Owen MJ, Goate AM, et al. Molecular genetics of Alzheimer's disease. Biochem Soc Trans. 1989;17(1):75-76. (Pubitemid 19052439)
21. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. (Pubitemid 38269583)
22. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′- methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23(6):2086-2092. (Pubitemid 36368896)
23. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25(46):10598-10606. (Pubitemid 41681907)
24. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15(4):869-877, xi-xii.
25. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431-434. (Pubitemid 46425701)
26. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(pt 6):1630-1645. (Pubitemid 351806448)
27. Kida E, Wisniewski KE, Wisniewski HM. Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of betapeptide in Alzheimer's disease and Down's syndrome brain. Neurosci Lett. 1995;193(2):105-108.
28. Schmidt ML, Robinson KA, Lee VM, Trojanowski JQ. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am J Pathol. 1995;147(2):503-515.
29. Sarsoza F, Saing T, Kayed R, et al. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 2009;118(4):505-517.
30. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129(pt 11):2856-2866. (Pubitemid 44684508)
31. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68(7):501-508.
32. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
33. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456-1465.
34. Jack CR Jr, Lowe VJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(pt 5):1355-1365.
35. Chételat G, Villemagne VL, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317-324.
36. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
37. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800. (Pubitemid 34663580)
38. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009;73(15):1186-1192.
39. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358-368.
40. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110(4):1129-1134.
41. Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down's syndrome: an atheroma-free model? Br Med J. 1977;2(6081):226-228.
42. Ylä-Herttuala S, Luoma J, Nikkari T, Kivimäki T. Down's syndrome and atherosclerosis. Atherosclerosis. 1989;76(2-3):269-272. (Pubitemid 19101046)
43. van de Louw J, Vorstenbosch R, Vinck L, Penning C, Evenhuis H. Prevalence of hypertension in adults with intellectual disability in the Netherlands. J Intellect Disabil Res. 2009;53(1):78-84.
44. Ball SL, Holland AJ, Hon J, Huppert FA, Treppner P, Watson PC. The CAMDEX-DS: The Cambridge Examination for Mental Disorders of Older People With Down's Syndrome and Other Intellectual Disabilities. Cambridge, England: Cambridge University Press; 2006.
45. Roth M, Huppert FA, Mountjoy CQ, Tym E. CAMDEX-R: The Cambridge Examination for Mental Disorders of the Elderly (Revised). Cambridge, England: Cambridge University Press; 1989.
46. Gregory CA, Hodges JR. Clinical features of frontal lobe dementia in comparison to Alzheimer's disease. J Neural Transm Suppl. 1996;47:103-123. (Pubitemid 26275592)
47. Ball SL, Holland AJ, Hon J, Huppert FA, Treppner P, Watson PC. Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study. Int J Geriatr Psychiatry. 2006;21(7):661-673. (Pubitemid 44122075)
48. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528-1547. (Pubitemid 41541962)
49. Kinahan PE, Rogers JG. Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci. 1989;36(1):964-968. doi:10.1109/23.34585.
50. Mazziotta JC, Toga A, Evans A, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci. 2001;356(1412):1293-1322. (Pubitemid 32876067)
51. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19(3):1233-1239. (Pubitemid 36918259)
52. Mann DM, Royston MC, Ravindra CR. Some morphometric observations on the brains of patients with Down's syndrome: their relationship to age and dementia. J Neurol Sci. 1990;99(2-3):153-164. (Pubitemid 20387374)
53. Lalowski M, Golabek A, Lemere CA, et al. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem. 1996;271(52):33623-33631.
54. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-1539. (Pubitemid 47301451)
55. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840. (Pubitemid 26292051)
56. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452. (Pubitemid 44214969)
57. Fripp J, Bourgeat P, Acosta O, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage. 2008;43(3):430-439.